MedTrace Logo

Effect of Aerobic Training on Oxidative Stress Markers in Patients With Parkinson's Disease

NCT05511402 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-08-25

No results posted yet for this study

Summary

Parkinson's disease is a chronic, neurodegenerative disorder characterized with the loss of dopamine-producing neurons. This loss is likely to be related with several environmental and genetic factors. One of the most important factor that is responsible for the initation and progression of the disease is oxidative stress. Exercise training, especially aerobic training, can change the levels of oxidative markers because exercise can lead to decrease oxidative stress in patients with Parkinson's disease. Therefore, this study aims to investigate (1) the effect of aerobic training on total antioxidant status, total oxidant status, glutathione, oxidative glutathione, and zonulin levels, (2) the relationship between the change of motor symptoms and disease severity and the change of total antioxidant status, total oxidant status, glutathione, oxidative glutathione, and zonulin levels.

Conditions

  • Parkinson Disease

Interventions

OTHER

Exercise training

People with Parkinson's Disease will be received a supervised physiotherapy and rehabilitation program.

Sponsors & Collaborators

  • Gazi University

    collaborator OTHER

  • Saglik Bilimleri Universitesi

    lead OTHER

Principal Investigators

  • Ayse Bora Tokcaer, Prof. Dr. · Gazi University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-25
Primary Completion
2022-11-30
Completion
2022-12-10

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05511402 on ClinicalTrials.gov